1. Scrip
  2. >>Business
  3. >>Deals

Gilead Adds To Virology Focus Through 12-Year Collaboration With Assembly

 
• By Joseph Haas

Gilead gets option rights to Assembly’s entire virology pipeline, including future assets, for herpesvirus and hepatitis B and D. The deal provides financial stability and opt-in potential for Assembly.

Virus. Digital illustration of Herpes virus. Realistic image of microbe, microorganism, microscopic view - Illustration
Gilead looks to Assembly for novel HSV, hep B and hep D candidates

Gilead Sciences, Inc. has historically focused on virology, with blockbuster products for HIV, hepatitis C and hepatitis B, but more recently has looked to broaden its therapeutic focus, particularly into oncology. Now the company appears to be re-emphasizing its core strength, signing a 12-year collaboration on 17 October with Assembly Biosciences, Inc. that will give it opt-in rights on all current and future pipeline candidates across herpesvirus, hepatis B virus (HBV) and hepatitis D.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome

 
• By Joseph Haas

Plus deals involving Spruce/BioMarin, Boehringer Ingelheim/Cue, Onconetix/Ocuvex, Allakos/Concentra, Sanofi/Nurix, Pfizer/Flagship Pioneering, Alcon/Aurion and more.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

More from Business

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.